The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,800
circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
Renmin Hospital of Wuhan University
Wuhan, Hubei, China
RECRUITINGNumber of participants with all-cause death
Time frame: 3 month
Number of participants with all-cause death
Time frame: 12 month
Number of participants with all-cause death
Time frame: 24 month
Number of participants with all-cause death
Time frame: 36 month
severe blooding complications
Time frame: 3 month
severe blooding complications
Time frame: 12 month
severe blooding complications
Time frame: 24 month
severe blooding complications
Time frame: 36 month
cardio-cerebrovascular complications
Time frame: 3 month
cardio-cerebrovascular complications
Time frame: 12 month
cardio-cerebrovascular complications
Time frame: 24 month
cardio-cerebrovascular complications
Time frame: 36 month
Number of participants with cardiovascular death events
Time frame: 3 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of participants with cardiovascular death events
Time frame: 12 month
Number of participants with cardiovascular death events
Time frame: 24 month
Number of participants with cardiovascular death events
Time frame: 36 month
recurrence of atrial arrhythmias (AF, AFL, AT)
Time frame: 3 month
recurrence of atrial arrhythmias (AF, AFL, AT)
Time frame: 12 month
recurrence of atrial arrhythmias (AF, AFL, AT)
Time frame: 24 month
recurrence of atrial arrhythmias (AF, AFL, AT)
Time frame: 36 month
resource utilization and costs
Time frame: 12 month
resource utilization and costs
Time frame: 24 month
resource utilization and costs
Time frame: 36 month